Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034476 | A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis | PHASE1 | COMPLETED | 466 | — | — | Oct 1, 2001 | Oct 1, 2002 | Jul 19, 2006 | 85 | United States, Belgium +3 |
| Name | Type | Description |
|---|---|---|
| sPLA2 Inhibitor | DRUG | - |
Inclusion Criteria: Patients must * show evidence of acute infection * meet specified time windows * be 18 years of age or older Exclusion Criteria: Patients must not * have low white blood cell count * have undergone certain organ transplants * be HIV positive * be pregnant or breast feeding * h...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 1 | PHASE2 | Nogapendekin alfa inbakicept |
| Bluejay Diagnostics, Inc. | BJDX | 2 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |
| Danaher Corporation | DHR | 3 | — | Undisclosed |
| Spectral AI, Inc. Class A | MDAI | 1 | NA | Undisclosed |